Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection.
Arterial stiffness
COVID-19 infection
Endothelial glycocalyx
Heart failure
Myocardial deformation
Oxidative stress
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
20
07
2021
received:
10
03
2021
accepted:
08
08
2021
pubmed:
21
8
2021
medline:
15
12
2021
entrez:
20
8
2021
Statut:
ppublish
Résumé
SARS-CoV-2 infection may lead to endothelial and vascular dysfunction. We investigated alterations of arterial stiffness, endothelial coronary and myocardial function markers 4 months after COVID-19 infection. In a case-control prospective study, we included 70 patients 4 months after COVID-19 infection, 70 age- and sex-matched untreated hypertensive patients (positive control) and 70 healthy individuals. We measured (i) perfused boundary region (PBR) of the sublingual arterial microvessels (increased PBR indicates reduced endothelial glycocalyx thickness), (ii) flow-mediated dilatation (FMD), (iii) coronary flow reserve (CFR) by Doppler echocardiography, (iv) pulse wave velocity (PWV), (v) global left and right ventricular longitudinal strain (GLS), and (vi) malondialdehyde (MDA), an oxidative stress marker, thrombomodulin and von Willebrand factor as endothelial biomarkers. COVID-19 patients had similar CFR and FMD as hypertensives (2.48 ± 0.41 vs. 2.58 ± 0.88, P = 0.562, and 5.86 ± 2.82% vs. 5.80 ± 2.07%, P = 0.872, respectively) but lower values than controls (3.42 ± 0.65, P = 0.0135, and 9.06 ± 2.11%, P = 0.002, respectively). Compared to controls, both COVID-19 and hypertensives had greater PBR5-25 (2.07 ± 0.15 µm and 2.07 ± 0.26 µm, P = 0.8 vs. 1.89 ± 0.17 µm, P = 0.001), higher PWV (carotid-femoral PWV 12.09 ± 2.50 vs. 11.92 ± 2.94, P = 0.7 vs. 10.04 ± 1.80 m/s, P = 0.036) and impaired left and right ventricular GLS (-19.50 ± 2.56% vs. -19.23 ± 2.67%, P = 0.864 vs. -21.98 ± 1.51%, P = 0.020 and -16.99 ± 3.17% vs. -18.63 ± 3.20%, P = 0.002 vs. -20.51 ± 2.28%, P < 0.001). MDA and thrombomodulin were higher in COVID-19 patients than both hypertensives and controls (10.67 ± 0.32 vs 1.76 ± 0.03, P = 0.003 vs. 1.01 ± 0.05 nmol/L, P = 0.001 and 3716.63 ± 188.36 vs. 3114.46 ± 179.18 pg/mL, P = 0.017 vs. 2590.02 ± 156.51 pg/mL, P < 0.001). Residual cardiovascular symptoms at 4 months were associated with oxidative stress and endothelial dysfunction markers. SARS-CoV-2 may cause endothelial and vascular dysfunction linked to impaired cardiac performance 4 months after infection.
Identifiants
pubmed: 34415085
doi: 10.1002/ejhf.2326
pmc: PMC8426810
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1916-1926Informations de copyright
© 2021 European Society of Cardiology.
Références
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
Lancet Haematol. 2020 Aug;7(8):e575-e582
pubmed: 32619411
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Eur J Heart Fail. 2020 Jun;22(6):957-966
pubmed: 32412156
Eur Heart J Cardiovasc Imaging. 2017 May 01;18(8):833-840
pubmed: 28637227
Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):591-600
pubmed: 29596561
Front Immunol. 2020 Nov 23;11:557235
pubmed: 33329516
Food Chem Toxicol. 2020 Jul;141:111389
pubmed: 32343994
Hypertension. 2004 Feb;43(2):176-81
pubmed: 14698999
Atherosclerosis. 2008 Jun;198(2):332-7
pubmed: 18164712
JACC Cardiovasc Imaging. 2012 Nov;5(11):1079-85
pubmed: 23153906
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Can J Cardiol. 2015 Mar;31(3):287-95
pubmed: 25660150
J Pathol. 2006 Nov;210(3):288-97
pubmed: 17031779
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Microcirculation. 2021 Apr;28(3):e12654
pubmed: 32791568
Eur J Heart Fail. 2015 Dec;17(12):1240-51
pubmed: 26443037
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
Hypertension. 2021 Mar 3;77(3):856-867
pubmed: 33377393
Microvasc Res. 2020 Nov;132:104064
pubmed: 32841626
Lancet. 1992 Nov 7;340(8828):1111-5
pubmed: 1359209
Ann Intensive Care. 2020 May 20;10(1):60
pubmed: 32436075
Angiogenesis. 2021 Feb;24(1):145-157
pubmed: 33058027
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Appl Physiol (1985). 2008 Mar;104(3):845-52
pubmed: 18162484
Clin Res Cardiol. 2016 Mar;105(3):248-56
pubmed: 26349786
Eur J Heart Fail. 2019 Apr;21(4):402-424
pubmed: 30859669
Intensive Care Med. 2020 Jun;46(6):1124-1126
pubmed: 32328726
Food Chem Toxicol. 2020 Nov;145:111694
pubmed: 32822775
Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H404-H410
pubmed: 33306450
Eur J Cardiovasc Prev Rehabil. 2011 Dec;18(6):775-89
pubmed: 21450600
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623